Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IIa Trial to Evaluate the Safety, Tolerability and Efficacy After Single Administration of TO-O-1007 (Intravitreal Implant) in Subjects With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

NCT07668804 is registered in ClinicalTrials.gov with Theratocular Biotek Co. as lead sponsor.

NCT NCT07668804
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07668804 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IIa Trial to Evaluate the Safety, Tolerability and Efficacy After Single Administration of TO-O-1007 (Intravitreal Implant) in Subjects With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
Lead sponsor
Theratocular Biotek Co.
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 2, 2026
Completion date
December 31, 2027
Enrollment
31 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

geographic atrophy due to age-related macular degeneration